Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: Results from the TEMPO 3:4 trial

TEMPO 3:4 Trial Investigators

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: Results from the TEMPO 3:4 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences